22117-79-9

Usage

Uses

Used in Organic Synthesis:
4-methoxy-3-nitrobenzenesulphonyl chloride is used as a reagent for the introduction of the sulphonyl chloride functional group in various chemical reactions. Its reactivity allows for the formation of new chemical bonds and the synthesis of complex organic molecules.
Used in Pharmaceutical Industry:
In the pharmaceutical industry, 4-methoxy-3-nitrobenzenesulphonyl chloride is used as an intermediate in the synthesis of various drugs. Its sulphonyl chloride group can be used to modify the structure of drug molecules, enhancing their pharmacological properties and therapeutic effects.
Used in Agrochemical Industry:
4-methoxy-3-nitrobenzenesulphonyl chloride is also employed in the agrochemical industry for the synthesis of pesticides and other agrochemicals. Its sulphonyl chloride group can be incorporated into the molecular structure of these compounds, improving their efficacy and selectivity in controlling pests and diseases.
Used in Dyes and Pigments Production:
In the production of dyes and pigments, 4-methoxy-3-nitrobenzenesulphonyl chloride is used as a key intermediate. Its unique chemical structure contributes to the color and properties of the resulting dyes and pigments, making it an important component in the formulation of various colorants used in different industries.

InChI:InChI=1/C7H6ClNO5S/c1-14-7-3-2-5(15(8,12)13)4-6(7)9(10)11/h2-4H,1H3

Upstream product

• 91-23-6 2-Nitroanisole 
• 98-68-0 4-methoxy-phenyl-sulphonyl chloride 

Downstream Products

• 50671-15-3 3-Nitro-4-methoxybenzolsulfo-4-dodecylanilid 
• 50671-28-8 4-Methoxy-3-nitrobenzolsulfo-(2-cetoxy)-anilid 
• 128887-33-2 N'-(3-nitro-4-methoxybenzenesulfonyl)-5-fluorouracil 
• 50671-16-4 3-Amino-4-methoxybenzolsulfo-4-dodecylanilid 
• 50671-17-5 α-(2-Chlorbenzoyl)-5--2-methoxyacetanilid 
• 50670-91-2 α-Chlor-α-(2-chlorbenzoyl)-5--2-methoxyacetanilid 
• 56807-21-7 2-methoxy-5-di-(β-hydroxyethyl)-sulphamoyl-aniline 
• 1179440-53-9 2-methoxy-5-di-(β-hydroxyethyl)-sulphamoyl-nitrobenzene 
• 22939-93-1 4-methoxy-3-nitro-benzenesulfonic acid amide 
• 823823-46-7 1-(4-methoxy-3-nitrobenzenesulfonyl)pyrrolidine 
• 16517-82-1 4-Methoxy-3-nitro-benzenesulfonic acid 1-amino-4-hydroxy-9,10-dioxo-9,10-dihydro-anthracen-2-yl ester 
• 1245240-16-7 C₁₅H₁₅ClN₂O₅S 
• 1245240-10-1 C₁₅H₁₅BrN₂O₅S 
• 1245240-03-2 C₁₄H₁₂Cl₂N₂O₆S 

Relevant academic research and scientific papers

New diarylsulfonamide inhibitors of Leishmania infantum amastigotes

New drugs against visceral leishmaniasis with mechanisms of action differing from existing treatments and with adequate cost, stability, and properties are urgently needed. No antitubulin drug is currently in the clinic against Leishmania infantum, the causative agent of visceral leishmaniasis in the Mediterranean area. We have designed and synthesized a focused library of 350 compounds against the Leishmania tubulin based on the structure-activity relationship (SAR) and sequence differences between host and parasite. The compounds synthesized are accessible, stable, and appropriately soluble in water. We assayed the library against Leishmania promastigotes, axenic, and intracellular amastigotes and found 0, 8, and 16 active compounds, respectively, with a high success rate against intracellular amastigotes of over 10%, not including the cytotoxic compounds. Five compounds have a similar or better potency than the clinically used miltefosine. 14 compounds showed a host-dependent mechanism of action that might be advantageous as it may render them less susceptible to the development of drug resistance. The active compounds cluster in five chemical classes that provide structure-activity relationships for further hit improvement and facilitate series development. Molecular docking is consistent with the proposed mechanism of action, supported by the observed structure-activity relationships, and suggests a potential extension to other Leishmania species due to sequence similarities. A new family of diarylsulfonamides designed against the parasite tubulins is active against Leishmania infantum and represents a new class of potential drugs with favorable cost, stability, and aqueous solubility for the treatment of visceral leishmaniasis (VL). These results could be extended to other clinically relevant species of Leishmania spp.

4-Acyl Pyrroles as Dual BET-BRD7/9 Bromodomain Inhibitors Address BETi Insensitive Human Cancer Cell Lines

Various malignant human diseases show disturbed signaling pathways due to increased activity of proteins within the epigenetic machinery. Recently, various novel inhibitors for epigenetic regulation have been introduced which promise a great therapeutic benefit. Inhibitors for the bromo- and extra-terminal domain (BET) family were of particular interest after inhibitors had shown a strong antiproliferative effect. More recently, the focus has increasingly shifted to bromodomains (BDs) outside the BET family. Based on previously developed inhibitors, we have optimized a small series of 4-acyl pyrroles, which we further analyzed by ITC, X-ray crystallography, selectivity studies, the NCI60 cell-panel, and GI50 determinations for several cancer cell lines. The inhibitors address both, BET and BRD7/9 BDs, with very high affinity and show a strong antiproliferative effect on various cancer cell lines that could not be observed for BD family selective inhibitors. Furthermore, a synergistic effect on breast cancer (MCF-7) and melanoma (SK-MEL-5) was proven.

CONDENSED PYRROLES AS NOVEL BROMODOMAIN INHIBITORS

Compounds of formula (1) or (2) and their use in the treatment of diseases or conditions for which a bromodomain inhibitor is indicated.

SULPHAMOYLARYL DERIVATIVES AND USE THEREOF AS MEDICAMENTS FOR THE TREATMENT OF LIVER FIBROSIS

Potent 5-HT2B antagonist of Formula (A), including stereochemically isomeric forms, and salts, hydrates, solvates thereof and their use wherein R1 to R4 and Ar have the meaning as defined herein. The present invention also relates to processes for preparing said compounds, pharmaceutical compositions containing them, alone or in combination with other drugs, in fibrosis and/or cirrhosis prevention or therapy.

7-HYDROXY-SPIROPIPIPERIDINE INDOLINYL ANTAGONISTS OF P2Y1 RECEPTOR

The present invention provides compounds of Formula (I): as defined in the specification and compositions comprising any of such novel compounds. These compounds are antagonists of Ρ2Y1 receptor and may be used as medicaments in the treatment and/or prophylaxis of thromboembolic disorders.

Pharmaceutical Compositions Comprising Nitrogen-Containing Fused Ring Coumpounds

[Problems] The present invention provides pharmaceutical composition which is effective for the prophylaxis or treatment of pathology showing involvement of uric acid (hyperuricemia, gouty tophus, acute gout arthritis, chronic gout arthritis, gouty kidney, urolithiasis, renal function disorder, coronary arterial disease, ischemic heart disease and the like) and the like, and is superior in the time-course stability and dissolution property (disintegration property). [Solving Means] The pharmaceutical composition of the present invention is a pharmaceutical composition comprising a nitrogen-containing fused ring compound represented by the following formula [1] or a pharmaceutically acceptable salt thereof, and one or more pharmaceutically acceptable additives, wherein the nitrogen-containing fused ring compound or a pharmaceutically acceptable salt thereof is not in contact with a basic additive: wherein each symbol is as described in the specification.

Production Method of Nitrogen-Containing Fused Ring Compounds

[Problems] The present invention provides a superior production method and a superior purification method of compounds effective for the treatment or prophylaxis of pathology showing involvement of uric acid, such as hyperuricemia, gouty tophus, acute gouty arthritis, chronic gouty arthritis, gouty kidney, urolithiasis, renal function disorder, coronary artery disease, ischemic heart disease and the like. [Means] A compound represented by the following formula [2] or a pharmaceutically acceptable salt thereof can be produced by reacting a compound represented by the following formula [3] or a salt thereof with a compound represented by the following formula [4], a salt thereof or a reactive derivative thereof. Moreover, crystallization of a compound represented by the formula [2] can be performed with industrially superior workability, and high quality crystals of a compound represented by the formula [2] can be obtained. wherein each symbol is as defined in the description.

Nitrogen-containing fused ring compounds and use thereof

A URAT1 activity inhibitor containing a nitrogen-containing fused ring compound represented by the following formula [1]: wherein each symbol is as defined in the description. The present invention is useful for the prophylaxis or treatment of pathology showing involvement of uric acid, such as hyperuricemia, gouty tophus, acute gouty arthritis, chronic gouty arthritis, gouty kidney, urolithiasis, renal function disorder, coronary artery disease, ischemic heart disease and the like.

Cell proliferation inhibitors

Compounds having formula (I) inhibit cellular proliferation. Processes for the preparation of the compounds, pharmaceutical compositions containing the compounds, and methods of treatment using the compounds are disclosed.

A novel method for the preparation of 3-amino-4-hydroxybenzenesulfonamide percursors of 'acid alizarin violet N' derivatives

Chlorosulfonation of 2-nitroanisole gave 4-methoxy-3-nitrobenzenesulfonyl chloride (7) which was converted with N-butyl(3-phenylpropyl)amine into benzenesulfonamide (8). Hydrolysis of the ether and reduction of the nitro group of 8 followed by diazotization and coupling with 2-naphthol gave N-butyl-N-(3-phenylpropyl)-4-hydroxy-3-(2-hydroxy-1- naphthyl)azobenzenesulfonamide (1d).